
Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target
Regeneron Pharmaceuticals (REGN) Analyst Ratings
Bulls say
Regeneron Pharmaceuticals is supported by a durable commercial base, led by Dupixent’s $6.54B global sales and Eylea HD’s record $699M U.S. quarter, which helped drive total revenue of $5.116B and non-GAAP EPS of $20.07, both well above expectations. Its outlook is strengthened by the first full quarter of profit share from the Sanofi alliance after the development balance was repaid, plus a $1B upfront to be recognized in 4Q26, alongside gross margin guidance rising to about 86% and share repurchases supporting earnings power. Beyond the core franchises, a broad pipeline in ophthalmology, immunology, oncology, and genetic medicine offers multiple shots on goal, while cash of about $18.9B leaves room to fund growth without sacrificing financial flexibility.
Bears say
Regeneron Pharmaceuticals is facing a negative outlook because its core Eylea franchise is exposed to accelerating biosimilar erosion, new biologic competition, patent risk, and slower-than-expected patient migration to Eylea HD, all of which could pressure revenue and market share. The company also faces moderating Dupixent growth as recent indication launches annualize, uncertainty around Dupixent’s life cycle, and the possibility that expansion into new indications or Libtayo and other pipeline programs may not offset mature-product headwinds. Despite a strong R&D engine and medium-term growth opportunities, near-term upside appears limited by clinical and regulatory setbacks, U.S. pricing pressure, and the risk that higher R&D investment in 2027 further compresses returns.
This aggregate rating is based on analysts' research of Regeneron Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Regeneron Pharmaceuticals (REGN) Analyst Forecast & Price Prediction
Start investing in Regeneron Pharmaceuticals (REGN)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Regeneron Pharmaceuticals (REGN) Forecast
Regeneron Pharmaceuticals (REGN) Analyst Forecast & Price Prediction
Start investing in Regeneron Pharmaceuticals (REGN)
Order type
Buy in
Order amount
Est. shares
0 shares